Reduce Parkinson’s progress speed by discovering a deadly molecule

According to RCO News Agency, The ancient program of “cell suicide”, called apoptosis, is regulated by interactions between family members of the Lymph -cell Protein 2. Some of these proteins strengthen the survival of the cell, while others cause cell death. Scientists have been able to inhibit some of the deaths of these proteins to treat some blood cancers.

Now, a group led by the Walter and Eliza Hall Medical Research Institute in Melbourne, Australia, have discovered in a new study of how to act in the opposite and targeting one of these proteins, blocking cell death and bringing a door to treatments such as disease progression.

Professor Grant Dewson, author of the study and head of the Parkinson’s Center for Research, says: “There is currently no treatment that prevents the death of neurons and slows Parkinson’s progress.” Any drug that can do this can be transformed.

Antagonist/Lymphoma Blind and X protein associated with lymphoma 2 cells B family proteins are BCL-2 proteins that cause cell death by penetrating the mitochondrial wall, which produces cell energy. When antagonist/cell lymphoma and X protein -based associated Lymphoma -B -cells do not function properly, it can lead to disorder in apoptosis, which helps autoimmune and neurological deterioration.

Given this, the researchers, relying on the very high screening capabilities of the National Center for Drug Discovery, examined the compound to identify the compound that targets a deadly protein protein of the X protein -related protein -related Lymphoma.

“We were very excited to find a small molecule that targets and stops its performance,” says Professor Guillaume Lesne, a colleague author and head of the medical department. Although this does not happen in most cells, in neurons, turning off the X protein -related Lymphoma 2 can alone may be sufficient to limit cell death.

Small molecules are low molecular organic compounds that are often used in the development of the drug because of their ability to pass the cell membrane and interact with intra -cell proteins. The researchers observed that the small molecule they identified, called Wehi-1, inhibits the ability of the X-related X protein-related protein to break the cell mitochondria and prevent it from dying.

For the first time, we were able to keep the X protein -related protein from the mitochondrial lymphoma and keep the cells alive using this molecule. This can pave the way for the next -generation cell death inhibitors to combat neurological deterioration.

The end of the message